Inactive Instrument

Momenta Pharmaceuticals, Inc.

Equities

MNTA

US60877T1007

Biotechnology & Medical Research

Momenta Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

May 02, 2019 at 04:30 pm IST

Momenta Pharmaceuticals Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced total revenue was USD 4.113 million compared to USD 4.852 million a year ago. Operating income was USD 48.091 million compared to USD 49.002 million a year ago. Net loss was USD 44.843 million compared to USD 47.631 million a year ago. Basic loss per share was USD 0.46 compared to USD 0.63 a year ago.

Latest news about Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc. Announces Executive Changes	02/20/02	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P TMI Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P 1000	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P Global BMI Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P Biotechnology Select Industry Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P 600 Health Care	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P Composite 1500	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P 600	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell Small Cap Comp Value Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Value Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Value Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 3000 Value Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell Small Cap Comp Growth Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Growth Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Growth Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 3000 Growth Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell Small Cap Completeness Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 3000 Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Value-Dynamic Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Growth-Dynamic Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Value-Dynamic Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Dynamic Index	01/20/01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Dynamic Index	01/20/01	CI

Chart Momenta Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	118B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.4B
ARGENX SE	-1.69%	21.78B
GENMAB A/S	-10.60%	18.09B
WUXI APPTEC CO., LTD.	-41.25%	16.72B
BEIGENE, LTD.	-15.33%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.03B
SAREPTA THERAPEUTICS, INC.	+28.03%	11.67B

Bio Therapeutic Drugs